SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination

Most studies of immunity to SARS-CoV-2 focus on circulating antibody, giving limited insights into mucosal defences that prevent viral replication and onward transmission. We studied nasal and plasma antibody responses one year after hospitalisation for COVID-19, including a period when SARS-CoV-2 v...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	EBioMedicine 2023-01, Vol.87, p.104402-104402, Article 104402
Hauptverfasser:	Cross, Andy, Siggins, Matthew K., Holden, Karl, Liggi, Sonia, Pius, Riinu, Tait, Sarah, Coutts, Audrey, Hafezi, Katarzyna, Bassford, Christopher, Berridge, John, Hartshorn, Stuart, Jacobs, Michael, Kelsey, Michael, Lillie, Patrick, Linnett, Vanessa, Minton, Jane, Mulla, Rohinton, Pintus, Stefania, Shanmuga, Prad, Spittle, Nick, Vincent, Rachel, Wilson, Lawrence, Wiselka, Martin, Young, Peter, Ashworth, Milton, Dunn, Chris, Fisher, Lewis W.S., Murphy, Ellen G, Adrego, R., Aguilar Jimenez, L.A., Ahmed, R., Arnold, H., Bailey, L., Bates, A., Beirne, P., Bisnauthsing, K., Brown, A., Burn, D., Burns, G., Calvelo, E., Carson, G., Carter, P., Cavanagh, J., Channon, K.M., Chinoy, H., Choudhury, G., Clark, D., Cooper, J., Coupland, C., Cox, E., Crisp, P., Crooks, M.G., Deas, C., Dharmagunawardena, R., Dixon, M., Evans, D., Fairman, A., Flynn, M., Ford, A., Gleeson, F., Gorsuch, T., Guillen Guio, B., Harrison, P., Heller, S., Ho, L.P., Humphries, A., Jackson, T., Jezzard, P., Jones, H., Kaltsakas, G., Keenan, N., Klenerman, P., Linford, S., Mallison, G., March, K., Mariveles, M., Martineau, A., Maskell, N., Newell, H., Ostermann, M., Pendlebury, J., Peto, T., Portukhay, S., Price, A., Reed, A., Rostron, A., Roy, K., Sanderson, A., Selby, N., Sharpe, C., Smith, J., Solstice, A.R., Teixeira, J., Tobin, M., West, S., Wild, J., Williams, N., Willoughby, J., Wright, L., Wright, S.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antibodies, Neutralizing Antibodies, Viral Convalescent COVID-19 COVID-19 - prevention & control COVID-19 Vaccines Follow-Up Studies Hospitalization Humans Immunoglobulin A Immunoglobulin G Mucosal immunity Nasal antibody SARS-CoV-2 SARS-CoV-2 immunity SARS-CoV-2 variants Vaccination
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Most studies of immunity to SARS-CoV-2 focus on circulating antibody, giving limited insights into mucosal defences that prevent viral replication and onward transmission. We studied nasal and plasma antibody responses one year after hospitalisation for COVID-19, including a period when SARS-CoV-2 vaccination was introduced. In this follow up study, plasma and nasosorption samples were prospectively collected from 446 adults hospitalised for COVID-19 between February 2020 and March 2021 via the ISARIC4C and PHOSP-COVID consortia. IgA and IgG responses to NP and S of ancestral SARS-CoV-2, Delta and Omicron (BA.1) variants were measured by electrochemiluminescence and compared with plasma neutralisation data. Strong and consistent nasal anti-NP and anti-S IgA responses were demonstrated, which remained elevated for nine months (p
ISSN:	2352-3964 2352-3964
DOI:	10.1016/j.ebiom.2022.104402